Immediate Impact
3 standout
Citing Papers
Recent advances in targeted strategies for triple-negative breast cancer
2023 Standout
Guidelines for the Prevention and Treatment of Chronic Hepatitis B (version 2022)
2023 Standout
Works of Harald-Robert Bruch being referenced
First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: Real-world experience from >2000 patients treated in the multicentre AVANTI study
2021
Treatment of chronic hepatitis B with interferon α-2b and interleukin-2
1993
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Harald-Robert Bruch | 2 | 5 | 19 | 17 | 7 | 29 | |
| Andrew Sloss | 3 | 17 | 17 | 6 | 35 | ||
| Jovan Basho | 5 | 14 | 14 | 8 | 41 | ||
| Franklin M. Hanger | 1 | 4 | 13 | 7 | 5 | 35 | |
| Nicholas Hannah | 4 | 9 | 10 | 6 | 23 | ||
| F Tobori | 6 | 13 | 14 | 6 | 25 | ||
| Waseem Hamoudi | 1 | 3 | 23 | 17 | 7 | 33 | |
| Abate Bane Shewaye | 7 | 14 | 13 | 7 | 35 | ||
| Arthur Paredes Gatti | 2 | 8 | 10 | 9 | 8 | 26 | |
| Hany Elbeshbeshy | 2 | 6 | 26 | 29 | 9 | 42 | |
| Huihong Huang | 3 | 13 | 7 | 6 | 23 |
All Works
Login with ORCID to disown or claim papers
Loading papers...